Reyon Pharmaceutical Co Ltd
102460
Company Profile
Business description
Reyon Pharmaceutical Co Ltd is a Korea-based pharmaceutical company. It is engaged in the manufacturing and distribution of specialty medicines and raw materials. The main business of the company has been divided into generic drugs, original drugs, and drug substances The key products include eye drops, injection, antibiotics, skeletal muscle relaxants, coagulation drugs, anti-inflammatory enzymes, and blood vessels dialectic drugs, among others.
Contact
416, Yeongdong-daero
8th floor, Gangnam-gu
Seoul
KORT: +82 234075222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
445
Stocks News & Analysis
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,121.60 | 12.90 | 0.14% |
| CAC 40 | 8,509.64 | 24.00 | 0.28% |
| DAX 40 | 25,629.24 | 17.21 | 0.07% |
| Dow JONES (US) | 52,485.03 | 276.97 | 0.53% |
| FTSE 100 | 10,868.05 | 29.22 | -0.27% |
| HKSE | 26,048.48 | 164.05 | 0.63% |
| NASDAQ | 25,373.85 | 251.68 | 1.00% |
| Nikkei 225 | 62,917.49 | 1,444.53 | -2.24% |
| NZX 50 Index | 13,722.78 | 23.50 | 0.17% |
| S&P 500 | 7,489.72 | 52.09 | 0.70% |
| S&P/ASX 200 | 8,958.90 | 9.90 | 0.11% |
| SSE Composite Index | 3,811.14 | 21.12 | -0.55% |